International Journal of Family Medicine / 2013 / Article / Tab 3

Research Article

Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer: A Survey Comprising 174 GPs

Table 3

Subtables comparing the GPs responses to whether they would measure PSA and their rationale behind PSA indication for asymptomatic patients.

GPs responses to the corresponding questions regarding their rationale behind the PSA indication. PSA indication*, n (%) value
YesNoDo not know

Case A
All patients over the age of 70 should have measured PSA.
 Yes0 (0.0)1 (1.1)0 (0.0)1.000
 No0 (0.0)90 (94.7)1 (100.0)
 Do not know0 (0.0)4 (4.2)0 (0.0)
Patients with a life expectancy over 10 years should have measured PSA.
 Yes0 (0.0)1 (1.1)1 (100.0)0.021
 No0 (0.0)84 (89.4)0 (0.0)
 Do not know0 (0.0)9 (9.6)0 (0.0)

Case B
A PSA measurement should be performed to diagnose an early stage PC, hence reducing mortality.
 Yes2 (10.0)2 (3.8)1 (4.8)0.004
 No10 (50.0)44 (83.0)10 (47.6)
 Do not know8 (40.0)7 (13.2)10 (47.6)
All men in the age interval 55–69, requesting a PSA measurement, should have the opportunity.
 Yes17 (81.0)3 (5.7)4 (19.0)<0.001
 No2 (9.5)39 (73.6)1 (4.8)
 Do not know2 (9.5)11 (20.8)16 (76.2)

Case C
Concerned patients requesting a PSA measurement to exclude PC should have the opportunity.
 Yes17 (94.4)3 (4.7)1 (7.1)<0.001
 No0 (0.0)48 (75.0)3 (21.4)
 Do not know1 (5.6)13 (20.3)10 (71.4)
A patient well informed of advantages and disadvantages concerning PC screening should have the opportunity.
 Yes18 (100.0)20 (31.3)8 (57.1)<0.001
 No0 (0.0)27 (42.2)0 (0.0)
 Do not know0 (0.0)17 (26.6)6 (42.9)

The proportion of missing data was between 2.0% and 4.1%.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.